Latest Headlines

  1. Tivic Receives Two Investigational New Drug Applications For Entolimod For The Treatment Of Acute Radiation Syndrome (ARS) And Advanced Cancers 8/20/2025

    Tivic Health Systems, Inc., a diversified immunotherapeutics company, today announced it has received, from Statera Biopharma, two investigational new drug applications (INDs) for its lead candidate, Entolimod.

  2. Ginkgo Datapoints, Tangible Scientific, And Inductive Bio Partner To Deploy AI-Driven Lab-In-The-loop Workflows Across The Biopharma Industry 8/20/2025

    Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its Datapoints offering has entered into a new strategic partnership with Inductive Bio and Tangible Scientific to make AI-driven lab-in-the-loop drug discovery broadly accessible across the industry.

  3. Elix Provides AI Drug Discovery Platform 'Elix Discovery' To KYORIN Pharmaceutical 8/20/2025

    Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”), a Japan-based AI drug discovery company, is pleased to announce that KYORIN Pharmaceutical Co., Ltd. (Headquarters: Tokyo; hereinafter “KYORIN”) has adopted Elix Discovery (https://www.elix-inc.com/platform/), Elix’s proprietary AI-powered drug discovery platform.

  4. XtalPi Signs MOU With Dong-A ST For Joint Research And Development Of Immunology And Inflammation Therapies 8/19/2025

    XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases.

  5. A New Model Predicts How Molecules Will Dissolve In Different Solvents 8/19/2025

    Using machine learning, MIT chemical engineers have created a computational model that can predict how well any given molecule will dissolve in an organic solvent — a key step in the synthesis of nearly any pharmaceutical.

  6. N-Power Medicine Launches Industry's First Prospective External Control Arm Platform To Dramatically Accelerate Oncology Drug Development And Reduce Reliance On Randomization 8/19/2025

    N-Power Medicine, a company reimagining oncology drug development, today announced the launch of the industry’s first Prospective External Control Arm (ProECA) platform for pharmaceutical and biotechnology partners.

  7. RemeGen And Santen Enter Into Exclusive Licensing Agreement For Ophthalmic Innovative Drug RC28-E In Greater China And Asian Countries 8/19/2025

    RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd. ("Santen").

  8. VASTHERA Receives U.S. FDA Clearance To Initiate Phase 1 Clinical Trial Of Pulmonary Arterial Hypertension Drug Candidate, VTB-10 8/19/2025

    On August 6, 2025, VASTHERA Co., Ltd. announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for VTB-10, its drug candidate for pulmonary arterial hypertension (PAH), a rare, life-threatening disease marked by elevated blood pressure in the lung arteries.

  9. Skyhawk Therapeutics Announces Strategic Collaboration With Merck KGaA, Darmstadt, Germany To Discover Novel RNA-Targeting Small Molecules For Neurological Disorders 8/18/2025

    Skyhawk Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate RNA expression, today announces a strategic research collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company.

  10. Researchers Glimpse The Inner Workings Of Protein Language Models 8/18/2025

    Within the past few years, models that can predict the structure or function of proteins have been widely used for a variety of biological applications, such as identifying drug targets and designing new therapeutic antibodies.